Understand the source comparison
Best Research Peptides for MS Research: Mechanism Comparison
BPC-157 VEGF/PDGF upregulation for angiogenesis and oligodendrocyte support eNOS activation, reduced oxidative stress Subcutaneous or oral (15% bioavailability orally) 40–60% reduction in demyelination severity Strongest preclinical data for myelin repair. Lim
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF/PDGF upregulation for angiogenesis and oligodendrocyte support
- eNOS activation, reduced oxidative stress
- Subcutaneous or oral (15% bioavailability orally)
- 40–60% reduction in demyelination severity
- Strongest preclinical data for myelin repair. Limited human trials
- Thymosin beta-4
- Actin sequestration, T-regulatory cell promotion
- Th1/Th2 balance shift toward anti-inflammatory state
- Subcutaneous or intraperitoneal
- 35% reduction in lesion burden
- Selective immunomodulation without broad suppression. Phase II trial ongoing
- Cerebrolysin
- Neurotrophic factor activity (BDNF/NGF analogues)
- Axonal stabilisation, anti-apoptotic protein upregulation
- Intravenous (30 mL daily)
- 50% reduction in axonal transection
- Only peptide with published human MS trial data. Effect on disability progression modest
- MOTS-c
- AMPK activation, mitochondrial biogenesis
- PGC-1alpha upregulation, oxidative metabolism enhancement
- Intraperitoneal or intranasal
- 30% reduction in EAE severity
- Addresses energy failure component DMTs don't target. Synergistic with standard therapies
- Selank
- IL-6/TNF-alpha suppression via HPA axis
- Anxiolytic effects, microglial modulation
- Intranasal (preferred) or subcutaneous
- Not formally quantified in EAE models
- Best data for neuroinflammation control. No published MS trials yet
- Semax
- BDNF upregulation, microglial activation control
- Cognitive enhancement, synaptic plasticity support
- Mechanism overlaps with cerebrolysin but synthetic and batch-consistent